Health Care up as Viking Surges - Health Care Roundup

Dow Jones

Sep 23

Health-care companies rose as one obesity-drug maker surged following a promising clinical trial.

Viking Therapeutics shares jumped by roughly one-third after a study showed that patients taking its weight-loss injection could keep weight off even when switching to less frequent doses.

Danish Ozempic maker Novo Nordisk wallowed around recent lows, amid concerns about intensifying competition in the popular weight-loss category.

Swiss drug maker Roche said an obesity drug candidate met the main objectives of a midstage clinical trial by helping patients reduce their blood glucose and body weight.

A task force commissioned by Vice President JD Vance will remove as many as 750,000 enrollments from the Affordable Care Act's public exchanges, citing enrollee ineligibility and fraud.

Maze Therapeutics rallied after rival Vertex Pharmaceuticals reported positive study results for its kidney disease drug, stoking optimism about demand for kidney products.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/news/2669127919"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2669127919\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2669127919?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-23 05:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2669127919","market":"hk","top_or_hot":-1,"title":"Health Care up as Viking Surges - Health Care Roundup","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies rose as one obesity-drug maker surged following a promising clinical trial. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares jumped by roughly one-third after a study showed that patients taking its weight-loss injection could keep weight off even when switching to less frequent doses. \n</p>\n<p>\n  Danish Ozempic maker Novo Nordisk wallowed around recent lows, amid concerns about intensifying competition in the popular weight-loss category. \n</p>\n<p>\n  Swiss drug maker Roche said an obesity drug candidate met the main objectives of a midstage clinical trial by helping patients reduce their blood glucose and body weight. \n</p>\n<p>\n  A task force commissioned by Vice President JD Vance will remove as many as 750,000 enrollments from the Affordable Care Act's public exchanges, citing enrollee ineligibility and fraud. \n</p>\n<p>\n  Maze Therapeutics rallied after rival Vertex Pharmaceuticals reported positive study results for its kidney disease drug, stoking optimism about demand for kidney products. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Health Care up as Viking Surges - Health Care Roundup</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealth Care up as Viking Surges - Health Care Roundup\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-09-23 05:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies rose as one obesity-drug maker surged following a promising clinical trial. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares jumped by roughly one-third after a study showed that patients taking its weight-loss injection could keep weight off even when switching to less frequent doses. \n</p>\n<p>\n  Danish Ozempic maker Novo Nordisk wallowed around recent lows, amid concerns about intensifying competition in the popular weight-loss category. \n</p>\n<p>\n  Swiss drug maker Roche said an obesity drug candidate met the main objectives of a midstage clinical trial by helping patients reduce their blood glucose and body weight. \n</p>\n<p>\n  A task force commissioned by Vice President JD Vance will remove as many as 750,000 enrollments from the Affordable Care Act's public exchanges, citing enrollee ineligibility and fraud. \n</p>\n<p>\n  Maze Therapeutics rallied after rival Vertex Pharmaceuticals reported positive study results for its kidney disease drug, stoking optimism about demand for kidney products. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2669127919","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2669127919","pubTimestamp":1790111460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Health-care companies rose as one obesity-drug maker surged following a promising clinical trial.Viking Therapeutics shares jumped by roughly one-third after a study showed that patients taking its weight-loss injection could keep weight off even when switching to less frequent doses.Danish Ozempic maker Novo Nordisk wallowed around recent lows, amid concerns about intensifying competition in the popular weight-loss category.Swiss drug maker Roche said an obesity drug candidate met the main objectives of a midstage clinical trial by helping patients reduce their blood glucose and body weight.A task force commissioned by Vice President JD Vance will remove as many as 750,000 enrollments from the Affordable Care Act's public exchanges, citing enrollee ineligibility and fraud.Maze Therapeutics rallied after rival Vertex Pharmaceuticals reported positive study results for its kidney disease drug, stoking optimism about demand for kidney products.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LABU":"三倍做多标普生物-Direxion","BK4581":"高盛持仓","XLV":"健康照护类股ETF-SPDR","XBI":"SPDR S&P Biotech ETF","BK4588":"碎股"},"translate_title":"随着维京人的激增，医疗保健也随之增加 - 医疗保健综述","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XLV":1.5,"LABU":0.6,"XBI":0.6},"content_text":"Health-care companies rose as one obesity-drug maker surged following a promising clinical trial. \n\n\nViking Therapeutics shares jumped by roughly one-third after a study showed that patients taking its weight-loss injection could keep weight off even when switching to less frequent doses. \n\n\n  Danish Ozempic maker Novo Nordisk wallowed around recent lows, amid concerns about intensifying competition in the popular weight-loss category. \n\n\n  Swiss drug maker Roche said an obesity drug candidate met the main objectives of a midstage clinical trial by helping patients reduce their blood glucose and body weight. \n\n\n  A task force commissioned by Vice President JD Vance will remove as many as 750,000 enrollments from the Affordable Care Act's public exchanges, citing enrollee ineligibility and fraud. \n\n\n  Maze Therapeutics rallied after rival Vertex Pharmaceuticals reported positive study results for its kidney disease drug, stoking optimism about demand for kidney products.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}